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ABSTRACT: The human basal transcription factor TFIIH plays a central role in two distinct processes.
TFIIH is an obligatory component of the RNA polymerase II (RNAP II) transcription initiation complex.
Additionally, it is believed to be the core structure around which some if not all the components of the
nucleotide excision repair (NER) machinery assemble to constitute a nucleotide excision repairosome.
At least two of the subunits of TFIIH (XPB and XPD proteins) are implicated in the disease xeroderma
pigmentosum (XP). We have exploited the availability of the cloned XPB, XPD, p62, p44, and p34
genes (all of which encode polypeptide subunits of TFIIH) to examine interactions between in Vitrotranslated polypeptides by co-immunoprecipitation. Additionally we have examined interactions between
TFIIH components, the human NER protein XPG, and the CSB protein which is implicated in Cockayne
syndrome (CS). Our analyses demonstrate that the XPB, XPD, p44, and p62 proteins interact with each
other. XPG protein interacts with multiple subunits of TFIIH and with CSB protein.

Transcription mediated by RNA polymerase II (RNAP II)1
in human cells requires the participation of multiple initiation
factors (Chalut et al., 1994). Among these is a complex of
polypeptides called transcription factor IIH (TFIIH)1 comprising nine polypeptides encoded by the XPB (ERCC3),
XPD (ERCC2), p62, p52, p44, p34, CYCH, MO15, and
MAT1 genes [reviewed in Drapkin and Reinberg (1994), Roy
et al. (1994), Sheikhattar et al. (1995), and J.-M. Egly,
personal communication]. The XPB (ERCC3) and XPD
(ERCC2) genes encode polypeptides of 89 and 80 kDa
respectively (reviewed in Drapkin & Reinberg, 1994). Both
genes are required for the process of nucleotide excision
repair (NER)1 in addition to their role in RNA II transcription. Consistent with this requirement individuals from the
XP-B and XP-D genetic complementation groups of the
hereditary disease xeroderma pigmentosum (XP)1 are defective in NER and are exceptionally prone to skin cancer
associated with sunlight exposure [reviewed in Friedberg et
al. (1995)].
Individuals from the XP-B, XP-D, and XP-G complementation groups sometimes manifest clinical features typical
of a second hereditary disorder called Cockayne syndrome
(CS)1 (Broughton, et al., 1995; Nance & Berry, 1992;
Vermuelen et al., 1993, 1994; Weeda et al., 1990). The
combined XP/CS state results in severe developmental and
neurological problems in addition to the dermatological
features of XP (Nance & Berry, 1992). CS can also present
†
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without the clinical features of XP (Nance & Berry, 1992).
Such patients belong to one of two genetic complementation
groups designated CS-A and CS-B [reviewed in Friedberg
et al. (1995)]. The CSA and CSB genes have recently been
cloned and can encode proteins of ∼168 and ∼46 kDa,
respectively (Henning et al., 1995; Troelstra et al., 1992).
The function of these proteins is presently unknown. Cells
from CS-A and CS-B individuals are abnormally sensitive
to UV radiation and are defective in the preferential repair
of the template strand of transcriptionally active genes
(Venema et al., 1990).
A further genetic complexity stems from the observation
that certain individuals with a third hereditary disorder called
trichothiodystrophy (TTD)1 are also defective in NER
[reviewed in Friedberg et al. (1995)]. Some of these TTD
patients have been shown to carry mutations in the XPD gene
(Broughton et al., 1994; Stefanini et al., 1986, 1993a,b).
Additionally, the NER-defective phenotype of cells from a
TTD individual has been shown to be corrected by microinjection of purified XPB protein, thereby implicating the
XPB gene in TTD (Vermeulen et al., 1994b).
The multiple subunits of human TFIIH are genetically and
functionally conserved in the yeast Saccharomyces cereVisiae. The human XPB and XPD proteins, are represented
as the Ssl2 (Rad25) and Rad3 proteins respectively (Gulyas
& Donohue, 1992; Park et al., 1992), and the yeast homologs
of the p62 and p44 proteins are called Tfb1 (Gileadi et al.,
1992) and Ssl1, respectively (Humbert et al., 1994). As is
the case with human TFIIH components, the yeast Rad3,
Ssl2, Tfb1, and Ssl1 proteins are required for both NER and
RNAP II transcription (Feaver et al., 1993; Wang et al., 1994,
1995). The architecture of yeast TFIIH (designated factor
b in earlier literature) has been partially defined by analyzing
interactions between some of its subunits (Bardwell, L., 1992;
Bardwell, L., et al., 1994; Bardwell, A. J., et al., 1994). Ssl2
protein interacts specifically with Rad3 protein, which in turn
© 1996 American Chemical Society
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interacts with Ssl1 protein. The latter also interacts with
Tfb1 protein.
Both human and yeast TFIIH stably associate with other
proteins required for NER but which have no known function
in RNAP II transcription. For example, purification of
human TFIIH often yields a complex which is stably
associated with XPG (Mu et al., 1995) or XPC protein
(Drapkin et al., 1994). Additionally, human XPA protein
interacts with XPB protein and with purified TFIIH in Vitro
(Park et al., 1995). XPA protein also interacts with the NER
proteins ERCC1 and XPF and with replication protein A
(RPA)1 (Matsuda et al., 1995), which is also required for
NER (Aboussekhra et al., 1995; Mu et al., 1995). A stable
multiprotein complex designated the nucleotide excision
repairosome has been identified in extracts of yeast cells
(Svejstrup et al., 1995). This complex includes the six
known subunits of yeast TFIIH (Ssl2, Rad3, Ssl1, Tfb1, Tfb2,
Tfb3) as well as the NER proteins Rad1, Rad2, Rad4, Rad10,
and Rad14 (Svejstrup et al., 1994, 1995). Yeast Rad2 protein
has been shown to specifically interact with both the Ssl2
and Tfb1 subunits (Bardwell, A. J., et al., 1994b).
A definition of protein-protein interactions in human
TFIIH is expected to facilitate an understanding of the
assembly of the putative human nucleotide excision repairosome. Additionally, a definition of such interactions
may provide insights as to how mutations in the XPB, XPD,
and XPG genes can result in the simultaneous clinical
features of XP and CS or the clinical features of TTD. In
the present study we have utilized the techniques of in Vitro
transcription and translation of the cloned human XPB, XPD,
p62, p44, and p34 genes to examine interactions between
the proteins they encode and to map domains required for
these interactions. Our results indicate interactions involving
all five of these subunits of TFIIH. However, we have
identified some differences between specific protein-protein
interactions in human and yeast TFIIH. Additionally we
report here that the human NER protein XPG interacts with
multiple components of TFIIH and, surprisingly, with the
protein encoded by the CSB gene.
EXPERIMENTAL PROCEDURES
Plasmid pGEM4Z and RNasin RNase inhibitor were
purchased from Promega Biotechnology. In Vitro synthesis
of mRNA was carried out using either SP6 or T7 mMessage
mMachine mRNA synthesis kit from Ambion. Rabbit
reticulocyte lysates for in Vitro translation of mRNA were
obtained from Novagen. In Vitro translation grade [35S]methionine, Amplify fluorographic reagent, and prestained
molecular weight markers were from Amersham. Ready
protein scintillation cocktail was from Beckman. Buffersaturated phenol was from Amresco. Caffeine, isopropyl
thiogalactoside (IPTG), and 5-bromo-4-chloro-3-indoyl phosphate (X-gal) were from Sigma. Monoclonal antibodies to
c-Fos (Ab-2) and to c-Myc, recognizing the 9E10 epitope
(Ab1), and protein A-agarose were from Oncogene Science.
Restriction enzymes were from Bethesda Research Laboratories, New England BioLabs, or Promega. Chemicals and
reagents for SDS-polyacrylamide gel electrophoresis (SDSPAGE) were from Bio-Rad.
Transcription Plasmid Constructions. All 9E10 epitopetagged constructs were generated by cloning the gene
encoding a particular TFIIH component into the pGEM4Z-
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9E10 vector described previously (Bardwell, L., 1992;
Bardwell, L., et al., 1992; Bardwell, A. J., et al., 1994). This
vector contains a sequence encoding 10 amino acids of the
9E10- epitope (Kolodzeij & Young, 1991) followed by the
polylinker in the SP6 orientation. Cloning in-frame in these
sites followed by in Vitro transcription from the SP6 promoter
generated mRNA that was translated to yield 9E10 epitopetagged fusion proteins. These constructs are designated with
the prefix 9E. Cloning in the same polylinker but in the
opposite orientation resulted in constructs that produced
nontagged mRNA following transcription from the T7
promoter. For some genes mRNA was synthesized by
cloning in the vector pT3/T7 (Bardwell, 1992) in the T7
orientation. These were translated into native proteins. All
constructs were verified by restriction mapping.
XPB Gene. Plasmids p9E-XPB and pXPB were constructed by cloning two PCR- amplified products representing
the XPB gene. The 5′-end of the gene was amplified using
primers 5′-ATAGGGATCCATGGGCAAAAGAGACCGA3′ (A) and 5′- GTAGCCATTATT CTGCAGCTCCATCCAG-3′ (F). Primers (A) and (F) carried Bam HI and PstI
restriction sites (underlined), respectively. The 3′-region of
the gene was amplified by PCR using primers 5′-CTGGATGGAGCTGCAGAATAATGGCTAC-3′ (E) and 5'TATCGGATCCTGCCTAAGCATCATTTCCT-3′ (B).
These have restriction sites for PstI and BamHI, respectively
(B). The stop codon introduced by primer B at the end of
the XPB coding region is highlighted. These two PCR
products represent the entire coding region of the XPB gene
and were used to reconstitute full-length XPB cDNA.
Digestion of the 9E-XPB and XPB clones with the restriction
enzymes BglII, EcoRV, and AflII generated run-off transcripts that were translated in Vitro to yield the epitope-tagged
or nontagged proteins XPB1-387, XPB1-305, and XPB1-198,
respectively.
XPD Gene. The plasmid construct that encodes the cDNA
for the XPD gene has been previously described (Frederick
et al., 1994). This construct, designated pXPD, was used to
synthesize mRNA from the T7 promoter to yield native XPD
protein following in Vitro translation. Plasmid p9E-XPD was
constructed by three-way ligation of the 5′-end of the gene
on a BamHI-SphI fragment and the 3′-region on an SphIHindIII fragment. In Vitro translation of mRNA templates
derived from pXPD digested with PVuII, EagI, HincII, and
NcoI generated the polypeptides XPD1-434, XPD1-324,
XPD1-248, and XPD1-162, respectively. Similarly the 9EXPD construct yielded the epitope-tagged polypeptides 9EXPD1-434, 9E-XPD1-324, and 9E-XPD1-248.
p62 Gene. The p62 gene was amplified by PCR using
primers 5′- GGGGGATCCACCATGGCAACCTCATCTGAA-3′ and 5′- GGGGATCCGTAAGCATCATGGCCACCTCA-3′. Both primers have a BamHI site (underlined) that
facilitated cloning of this gene in-frame into the BamHI site
of pGEM4Z9E10, to generate p9Ep62. Epitope-tagged p62
protein was synthesized from this construct by translation
of mRNA directed from the SP6 promoter. Plasmid constructs carrying the p62 gene in the opposite orientation
yielded native p62 mRNA. Nontagged p62 mRNA did not
translate full-length polypeptide of 62 kDa, unlike epitopetagged p62 mRNA.
p44 Gene. The p44 gene was amplified using the primers
5′- TGAAAGGATCCATGAAGAACCTGAAAGAACT-3′
and 5′-GACCGGATCCTCAAACACCTGAAGGAGCT-
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GGA-3′. The BamHI sites (underlined) allowed cloning of
the gene in either orientation in the pGEM9E10 vector. The
plasmid construct p9Ep44 was used to produce 9E10 epitopetagged mRNA from the SP6 promoter. A clone carrying
the p44 insert in the opposite orientation (pNTp44) generated
native p44 mRNA from the T7 promoter. Run-off transcription from either construct linearized at the NheI and ScaI
restriction sites yielded the corresponding truncated polypeptides, p441-240 and p441-166 or 9E-p441-240 and 9E-p441-166.
p34 Gene. The p34 gene was amplified by PCR using
primers 5′- TATGAATTCATGGTTTCAGACGAAGATGAATTGAAT-3′ and 5′- TGGTCTAGATCAGTTTCTTTTCTTGGCTTTCAGCAC-3′. These primers introduced
EcoRI and XbaI sites (underlined). This allowed directional
cloning of the p34 gene in the pGEM9E10 vector (p9E-p34)
to produce epitope-tagged mRNA from the SP6 promoter
and in the pT3/T7 vector to produce p34 mRNA from the
T7 promoter. Run-off transcription from either constructs
linearized at HpaII and BamHI restriction sites generated
the truncated polypeptides p341-245 and p341-134, respectively, or 9E-p341-245 and 9E-p341-134.
XPG Gene. Plasmids p9E-XPG and pXPG were constructed using two truncated clones isolated from a HeLa
cell library. Restriction mapping, sequencing, and subcloning yielded a truncated clone missing a 1.2 kb region from
the N-terminus. This region was recovered by RT-PCR of
human B-cell RNA using a 3′ gene specific primer
XPG.GSP2R, 5′-GGCGGATCCGTCTGCACATCATCCCCAG-3′ and further amplification of the first-strand cDNA
using a 5′ primer, XPG.GSP22F, 5′-CCCCCGGGATCCGCTCTTAGGACGCAG-3′. The BamHI restriction sites
used in cloning the RT-PCR product is underlined. This
product was built into the truncated construct to go in-frame
and generate a full-length XPG cDNA . This cDNA was
subcloned in two steps, first as a BamHI-XbaI (3′-end)
fragment followed by a BamHI fragment covering the
remaining 5′-region, into the BamHI site of either pGEM
4Z vector or pGEM 4Z-9E10 vector carrying the epitopetag. Therefore, the synthesis of both the epitope-tagged and
nontagged XPG mRNA was directed from the SP6 promoter.
Digestion of the 9E-XPG and XPG gene with the restriction
enzyme AccI generated run-off transcripts that were translated
in Vitro to yield 9EXPG1-377 or XPG1-377, respectively.
Plasmid constructs expressing the epitope-tagged internal
domains of the XPG gene were generated by specifically
amplifying an appropriate region and cloning it in-frame.
The C-domain was amplified using the primer CDM.FOR
5′- CGGGATCCAACAGCAGAATTCACTGAAAGC-3′ and
primer CDM.REV 5′- CGGGATCCAGTTTTCAGTGAATTCTGCTGTGC-3′. The acidic region preceding the Cdomain was amplified using the primer AD. FOR 5′CGGGATCCAGCATGAGAATTTTCTGGAAAC 3′ and
primer AD.REV 5′ CGGGATCCAGTTTTCAGTGAATTCTGCTGTGC-3′. The BamHI restriction site involved in
cloning these fragments is underlined. All constructs were
linearized at the SalI site before transcription from the SP6
promoter to generate specific epitope-tagged mRNA.
CSB Gene. Plasmid p9E-CSB used in this study was
constructed by cloning two PCR products representing the
CSB gene that were amplified from a human cDNA library.
The 5′ portion of the gene was amplified using primers
(CSB.FOR) 5′-CAGGGATCCATGCCAAATGAGGGAATCCCCCACTCA-3′ and (6IRR) 5′-TTGTAAGCAGTTTTGA-

Biochemistry, Vol. 35, No. 7, 1996 2159
CCTGTACTGGGGAAGCATTTGAATATC-3′. The 3′ half
of the CSB gene was amplified with primer (6ILF) 5′CTGTGTTTATGGAGCAGTTCTCCGTCCCCATCAC-3′
and (CSB.Rev) 5′-AAGGGATCCTGTTTAGCAGTATTCTGGCTTGAGTTT-3′. These two PCR products represent the entire coding region of the CSB gene. The two
fragments were cloned in-frame by a three-way ligation using
an internal unique NcoI site in the overlapping region. The
flanking BamHI restriction sites built into the CSB.For and
CSB.Rev primers that were used for cloning the full-length
CSB gene into the pGEM 4Z-9E10 vector is underlined.
In Vitro Transcription. All templates for in Vitro transcription using either SP6 or T7 polymerases were generated
by linearizing with an appropriate restriction enzyme at the
3′-end of the coding region, or internally for C-terminal
deletions. Templates were purified by phenol-chloroform
extraction followed by passage through spin columns.
mRNA was synthesized in Vitro by using an SP6 or T7
mMessage mMachine kit per the manufacturer’s recommendations (Ambion). The mRNA was purified by phenolchloroform extraction and passed through a G-50 spin
column.
In Vitro Translation. Purified mRNA was used to program
specific translation reactions with rabbit reticulocyte lysates
(Novagen) in the presence of [35S]methionine at 30 °C.
Translation of epitope-tagged mRNA and control translations
that lacked mRNA were performed under identical conditions
except that these reactions did not contain labeled methionine. All translation products were partially purified by
ammonium sulfate precipitation as described previously
(Bardwell et al., 1992).
Immunoprecipitation. Immunoprecipitation reactions were
carried out in immunoprecipitation buffer (buffer A), consisting of 20 mM Tris (pH 7.5), 75 mM KCl, 5 mM sodium
bisulfite, 4 mM MgCl2, 0.5 mM EDTA, 1 mM DTT, 0.1%
Tween 20, 12.5% glycerol, and the protease inhibitors
pepstatin (1 µg/mL), leupeptin (1 µg/mL), and PMSF (1
mM). Immunoprecipitation was carried out essentially as
previously described (Bardwell, L., et al., 1992, 1994;
Bardwell, A. J., et al., 1994). Briefly, partially purified in
Vitro-translated proteins were resuspended in buffer A at
three times the translation volume. Aliquots (60 µL) each
of the two interacting proteins under analysis were mixed
with 80 µL of buffer A and incubated at 30 °C for 30 min.
These reactions were incubated for 1 h at room temperature
in the presence of 9E10 antibody-protein A-agarose complexes on a rocking platform. Protein complexes were
pelleted and washed at least three times with buffer A.
Following resuspension, aliquots were taken for measuring
radioactivity by liquid scintillation counting. Samples were
further analyzed by SDS-PAGE by running equal volumes
of test and control reactions on 10% or 15% gels followed
by fluorography. Protein-protein interactions were evaluated by comparing the amount of radioactivity immunoprecipitated by the antibody in the presence of epitope-tagged
protein to that precipitated nonspecifically in the absence of
epitope-tagged protein (background). Levels of radioactivity
at least 3-fold above background were considered positive
after multiple independent experiments.
Yeast Two-Hybrid System. All of the genes were cloned
into either the pAS1 (Durfee et al., 1993) vector, which when
introduced into yeast cells results in production of the Gal4
DNA-binding domain fused to the human protein, or into
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Table 1: Summary of Protein-Protein Interactions
proteins
tested

interaction observed
by co-immunoprecipitation

XPB/XPD
XPB/p62
XPB/p44
XPB/p34
XPD/p62
XPD/p44
XPD/p34
p34/p44
p34/p62
p44/p62
XPG/XPD
XPG/p62
XPG/CSB
XPG/XPD
XPG/p44
XPG/p34

+
+ (confirmed in two-hybrid system)
+
+
+
+
+
+
- (positive in two-hybrid system)
+
+
+
+
+
-

the pACT (Durfee et al., 1993) vector, resulting in the
production of the Gal4 transcriptional activation domain
fused to the human protein. The plasmids were introduced
into the strain Y190 [a cyhr derivative of Y153 (Durfee et
al., 1993)], and β-galactosidase activities were determined
as described (Bardwell, A. J., et al., 1993). For each
combination of plasmids eight to ten individual transformants
were grown and assayed. The plasmids were constructed
as follows:
pACTXPB: The XPB gene was amplified by PCR from
pGEMXPB using primers 5′-GGGGATCCGAATGGGCAAAAGAGACCG-3′ and 5′-GGGGATCCTCATTTCCTAAAGCGCTT-3′. Both primers have a BamHI site
(underlined) that facilitated cloning of the gene in-frame into
the BamHI site of pACT.
pAS1p62: The p62 gene was amplified by PCR from
pGEMp62 using primers 5′-GGGGATCCGAATGGCAACCTCATCTGA-3′, containing a BamHI site (underlined) and
5′-GGGGATCCGTCGACTCACGTTTTCTTCATCAG-3′,
containing a SalI site (underlined). The PCR product was
cloned into the pAS1 vector at the BamHI and SalI sites.
pACTp44: The p44 gene was PCR amplified using
primers 5′-GGGGATCCGAATGGATGAAGAACCTG-3′,
containing a BamHI site (underlined) and 5′-GGGGATCCGTCGACTCAAACACCTGAAGGAG-3′, containing a
SalI site (underlined). The PCR product was cloned into
the pACT vector using the BamHI and XhoI sites.
RESULTS
Protein-Protein Interactions in the TFIIH Complex. We
examined co-immunoprecipitation of TFIIH subunits incubated in multiple pairwise combinations following their
translation in Vitro as epitope-tagged or native proteins.
Native (nontagged) proteins were radiolabeled with [35S]methionine and monitored for co-precipitation with epitopetagged proteins by monoclonal antibodies to the humanspecific c-Myc epitope 9E10 (see Materials and Methods).
Protein-protein interactions were considered positive only
when they reproducibly yielded levels of radioactivity in the
precipitates more than 3-fold over background (see Materials
and Methods). This general technique for monitoring
protein-protein interactions is well established, and specific
refinements of the technique (Bardwell, L., 1992; Bardwell,
L., et al., 1992) have been successfully used in previous
studies on interactions between yeast NER proteins which

FIGURE 1: Interactions between XPB, XPD, and p62 proteins. (A)
XPB protein was translated in Vitro in the presence of [35S]methionine and precipitated with ammonium sulfate (lane 1; I )
input) or mixed with in Vitro-translated epitope-tagged p62 protein
(9Ep62) and precipitated in the presence of monoclonal antibodies
to the 9E10 epitope (lane 2). Lane 3 is a control precipitation
without in Vitro-translated epitope-tagged p62 protein. Equal
volumes (15 µL) of the immunoprecipitates with 9E10 monoclonal
antibody were analyzed. (B) The experiment described in A was
repeated using in Vitro-translated radiolabeled XPD protein and
epitope-tagged p62 (9Ep62) or XPB (9EXPB) proteins. Lane 1,
radiolabeled XPD protein; lane 2, radiolabeled XPD protein coprecipitated with 9EXPB protein; lane 3, radiolabeled XPD protein
co-precipitated with 9Ep62 protein, lane 4, control without epitopetagged proteins. Samples were analyzed by 10% SDS-PAGE and
by autoradiography. The positions of molecular mass markers (kDa)
are indicated on the left.

were independently confirmed in ViVo (Bardwell, L., et al.,
1992, 1994; Bardwell, A. J., 1993, 1994). In our experience
false positive reactions are not encountered. However, the
technique may fail to detect relatively weak protein-protein
interactions with a Kd < ∼10-7. The results of these
experiments revealed specific interactions among a number
of the TFIIH subunits. These are detailed in the ensuing
paragraphs. Specific interactions are shown in representative
figures, and the collective results are summarized in Table
1. In selected cases protein-protein interactions were also
examined in ViVo using the yeast two-hybrid genetic screen.
Interactions between XPB, p62, XPD, and p44 Proteins.
In vitro-translated radiolabeled XPB (ERCC3) protein coprecipitated with 9E10-tagged p62 protein (9Ep62) in the
presence of monoclonal antibody to the 9E10 epitope (Table
1, Figure 1A, lane 2). Precipitation of XPB protein was not
observed in the absence of 9Ep62 protein (Figure 1A, lane
3). An interaction between these two proteins was also
observed in ViVo. Specifically, when a yeast reporter strain
was transformed with two plasmids carrying the XPB gene
fused to the transcription activation domain of the yeast
GAL4 gene and the p62 gene fused to the DNA-binding
domain of GAL4, respectively, we observed and quantitated
(see Materials and Methods) increased expression of β-ga-
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FIGURE 2: Interaction between p44 and p34 and their interaction
with XPB, XPD and p62 proteins. (A) Radiolabeled in Vitrotranslated XPB (lane 1), XPD (lane 4), and p34 (lane 7) proteins (I
) input) were examined for co-immunoprecipitation with epitopetagged p44 protein (9Ep44) as described in the legend to Figure 1.
Equal volumes (15 µL) of immunoprecipitates (using 9E10
antibody) from reactions with XPB, XPD, or p34 proteins in the
presence (+) (lanes 2, 5, and 8, respectively) or absence (-) (lanes
3, 6, and 9, respectively) of 9Ep44 were analyzed. (B) Radiolabeled
in Vitro-translated p34 protein (lane 1) was examined for coimmunoprecipitation with epitope-tagged XPD protein (9EXPD)
(lane 2), XPB protein (9EXPB) (lane 3), p62 protein (9Ep62) (lane
4), or p44 protein (9Ep44) (lane 5). Lane 6 is a control without
epitope-tagged protein. Samples were analyzed by 10% SDSPAGE and by autoradiography. The positions of molecular mass
markers (kDa) are indicated on the left.

lactosidase relative to that observed with either plasmid alone
(data not shown). Several prematurely terminated XPB
polypeptides also co-precipitated with epitope-tagged p62
protein (Figure 1A, lane 2). Some of these truncated
polypeptides are about half the size of full-length XPB
protein, suggesting that the C-terminal half of XPB protein
is not required for its interaction with p62. This result was
directly confirmed by mapping domains of XPB protein
required for its interaction with p62 (see below).
Epitope-tagged XPB protein co-immunoprecipitated with
radiolabeled XPD protein (Table 1, Figure 1B, lane 2),
whereas XPD protein alone was not precipitated by the
antibody (Figure 1B, lane 4). In light of the observation
that XPB interacts with p62 protein (see above), we explored
an interaction between the XPD and p62 proteins. Radiolabeled XPD protein was indeed co-precipitated with 9Ep62
protein (Table 1, Figure 1B, lane 3). When epitope-tagged
p44 (9Ep44) was incubated with radiolabeled XPB or XPD
protein, we observed interactions in each case (Table 1 and
Figure 2A). We did not detect an interaction between p44
and 9Ep62 proteins by this technique (data not shown).
However, a strong interaction between these proteins was
observed in the two-hybrid system using plasmids expressing
p44 protein fused to the Gal4 transcriptional activation
domain and p62 protein fused to the Gal4 DNA binding
domain (Figure 3).
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FIGURE 3: Interactions between p62 and p44 proteins in the yeast
two-hybrid system. Transformants containing pAS1p62, pACTp44,
or both plasmids together were transferred to nitrocellulose filters,
which were immersed in liquid nitrogen and incubated in the
presence of 5-bromo-4-chloro-3-indoyl β-D-galactoside indicator.
A positive interaction is indicated by colonies turning blue
(p62+p44).

In summary, our results suggest that the four human TFIIH
components p62, XPB, XPD, and p44, whose known yeast
homologs Tfb1, Ssl2, Rad3, and Ssl1 respectively, are
required for NER and RNA polymerase II transcription, are
organized in a complex in which all four proteins interact
with each other.
p34 Interacts with p44, XPD, and XPB Proteins. p34 is
the smallest subunit of the TFIIH complex and has limited
amino acid sequence homology with p44 protein in the region
of a putative zinc-finger motif (Humbert et al., 1994). A
yeast homolog of p34 has not yet been identified. When
radiolabeled p34 was tested for its interaction with epitopetagged p44, p62, XPB, or XPD proteins, co-precipitation was
observed in all cases except with p62 (Table 1 and Figure
2A,B). A particularly strong interaction was observed
between p34 and p44 proteins on the basis of quantitative
measurements of radioactivity in immunoprecipitates (see
Materials and Methods).
XPG Protein Interacts with Multiple Components of TFIIH
and with CSB Protein. Purified preparations of TFIIH have
been reported to contain XPG protein (Mu et al., 1995).
Additionally, the yeast XPG homolog Rad2 has been shown
to interact with the Tfb1 (human p62) and Ssl2 (human XPB)
subunits and with purified yeast TFIIH (Bardwell et al.,
1994b). Radiolabeled in Vitro-translated XPB protein coprecipitated with epitope-tagged XPG protein (9E-XPG) in
the presence of monoclonal antibody to the epitope (Table
1, Figure 4A, lane 2). No precipitation of XPB protein was
observed in the absence of 9E-XPG protein (Figure 4A, lane
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FIGURE 4: XPG interacts with multiple proteins in Vitro. (A) In
Vitro-translated radiolabeled XPB protein co-precipitated with
epitope-tagged XPG (9EXPG) protein (lane 2). XPB protein was
not detected in the absence of 9EXPG. (B) In Vitro-translated
radiolabeled XPD protein co-precipitated with epitope-tagged XPG
(9EXPG) protein (lane 2). XPD protein was not detected in the
absence of 9EXPG. (C) Similar results are shown for the interaction
between in Vitro-translated radiolabeled XPG protein and epitopetagged p62 (9Ep62) protein. (D) Similar results are shown for the
interaction between in Vitro-translated radiolabeled XPG protein
and epitope-tagged p44 (9Ep44) protein. (E) In Vitro-translated
radiolabeled XPG protein did not interact with epitope-tagged p34
(9Ep34). (F) In Vitro-translated radiolabeled XPG protein coprecipitated with epitope-tagged CSB (9ECSB) protein (lane 2).

3). Further experiments established that XPG protein also
interacts with epitope-tagged p62 protein (Table 1, Figure
4C). Hence, as in yeast, human XPG protein (yeast Rad2)
interacts with the TFIIH subunits XPB (yeast Ssl2) and p62
(yeast Tfb1). We also observed interactions between XPG
protein and XPD and p44 proteins (Figure 4B,D). However,
we did not observe an interaction between XPG and p34
protein (Figure 4E).
Previous studies from this laboratory have demonstrated
an interaction between the proteins encoded by the human
CSA and CSB genes (Henning et al., 1995). CSA protein
also interacts with the p44 subunit of TFIIH, but not with
the p62, XPD, or XPB subunits (Henning et al., 1995).
These and other observations (see Discussion) suggest
possible roles of CSA and CSB proteins in RNAP II
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transcription. In the present studies we observed that
radiolabeled XPG protein was precipitated by the 9E10
antibody in the presence of epitope-tagged CSB protein
(Table 1, Figure 4F, lane 2) but not in its absence (Figure
4F, lane 3).
Specificity of Protein-Protein Interactions. The examination of protein interactions by co-immunoprecipitation of in
Vitro-translated polypeptides is a well-established technique.
However, this technology can be subject to both false positive
and false negative results that must be kept in mind when
interpreting results. We have attempted to minimize the
potential for spurious results in several ways. First, the
interactions reported above were all observed in the presence
of a several thousand-fold excess of nonspecific proteins
contributed by the reticulocyte lysates. Such a vast excess
of irrelevant protein is expected to effectively block “sticky”
sites which may contribute to nonspecific interactions.
Second, we have used a modified experimental system in
which translation products were partially purified by ammonium sulfate precipitation prior to mixing for immunoprecipitation. This procedure improves the sensitivity of the
detection of interacting proteins and reduces the potential
for nonspecific interactions (Bardwell, L., et al., 1992).
Third, in all cases the pairs of proteins tested represent equal
volumes of a single translation reaction. While the efficiency
of translation of individual mRNAs was not evaluated
quantitatively, it is unlikely that the relative amount of each
pair of proteins tested differed vastly. Fourth, the reticulocyte
lysates used were treated with micrococcal nuclease by the
manufacturer. Hence, the potential for false positive results
resulting from the binding of proteins to DNA rather to each
other is significantly reduced. Fifth, the interactions observed
obeyed appropriate specificity. Thus, the functionally irrelevant proteins c-Fos and c-Jun from human cells, Swi10
protein from Schizosaccharomyces pombe or Phr1 protein
from S. cereVisiae did not co-precipitate with several epitopetagged subunits of TFIIH (Figure 5A) or with XPG protein
(data not shown), whereas c-Fos protein was readily precipitated by specific anti-Fos antibodies (Figure 5A). Similarly, consistent with the observation that in Vitro-translated
or purified Rad1 and Rad10 proteins do not directly associate
with purified yeast TFIIH (Bardwell, L., et al., 1994), we
failed to observe interactions between in Vitro-translated
radiolabeled ERCC1 protein (the human homolog of Rad10
protein) and either XPB or p62 protein (Figure 5B). Sixth,
as noted above, our analysis of components of the human
TFIIH complex revealed interactions between some but not
all of them. Finally, it is conceivable that some protein pairs
may yield a false positive interaction because they are
bridged by interacting protein(s) in the rabbit reticulocyte
lysate. We know of no way to definitively rule out such a
possibility. This issue may be of serious concern in cases
where the test proteins in question are of unknown relationship. However, the proteins tested in these experiments are
all established members of the human TFIIH complex, and
hence the interactions observed are not unexpected.
Mapping Protein Interaction Domains of TFIIH Subunits.
In order to identify domains in individual polypeptides
required for interactions between various TFIIH subunits and
between XPG protein and TFIIH proteins we linearized DNA
templates at appropriate restriction sites, expressed run-off
transcripts, and translated them in Vitro. In many instances
these studies independently validated the results obtained
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FIGURE 5: (A) Epitope-tagged p62 protein does not co-immunoprecipitate with either radiolabeled in Vitro-translated Swi10 protein
of S. pombe (lane 2) or c-Fos protein (lane 5). However, c-Fos
protein is precipitated in the presence of antibodies to the protein
(lane 7). (B) In Vitro-translated human ERCC1 protein does not
co-precipitate with either epitope-tagged XPB (lane 2) or p62 (lane
3) proteins.

with full-length proteins. All truncated proteins were verified
for their reduced size. The results of these studies are
detailed below. A comprehensive summary of the mapping
data including a reiteration of interactions between full-length
proteins is presented in Figure 6, and the interaction domains
identified are represented schematically in Figure 7.
The p621-65 Polypeptide Is Sufficient for Interaction with
XPB and XPD Proteins. The smallest truncation of p62
tested (representing the N-terminal 65 amino acids) precipitated with both radiolabeled XPB and XPD proteins (Figure
6A). Quantitative analysis of the precipitates indicated that
these interactions were stronger than those observed using
full-length p62 protein. The observation that truncation of
a polypeptide can result in improved binding affinity with
cognate proteins has been previously reported (Bardwell, L.,
et al., 1992). Our data suggest that the N-terminal region
of p62 protein between amino acids 1 and 65 is required for
interaction with XPD and XPB proteins (Figure 7).
XPB and XPD Proteins HaVe Multiple Interaction Domains. The truncated polypeptide XPB1-387 interacted with
both p62 and p44 proteins, but the smaller polypeptides
XPB1-305 and XPB1-198 did not (Figure 6B). We conclude
that amino acid residues 305-387 of XPB protein are
required for interactions with both p62 and p44 proteins
(Figure 7). All three truncated XPB polypeptides interacted
with XPD and p34 proteins (Figure 6B). Hence, the domain
required for the interaction of XPB with both XPD and p34
proteins apparently resides within the first 198 amino acid
residues of the XPB polypeptide (Figure 7).
The truncated polypeptides XPD1-434, XPD1-324, and
XPD1-162 did not co-precipitate with p62 protein (Figure 6C).
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Apparently the region of the XPD protein between amino
acids 434 and the C-terminus is required for its interaction
with p62 protein (Figure 7). All three truncated XPD
polypeptides interacted with XPB protein (Figure 6C),
indicating that the XPB-interacting domain of XPD protein
is within the N-terminal 162 amino acids (Figure 7). Since
XPB protein also interacts with XPD protein through an
N-terminal domain (see above), we inquired whether just
these domains are sufficient for their interaction. We indeed
observed that XPD1-162 and XPB1-198 interacted strongly
(Figure 6C). The three truncated XPD polypeptides also coprecipitated with p44 protein. Polypeptides XPD1-434 and
XPD1-324 additionally interacted with p34 protein (Figure
6C). For technical reasons the smallest polypeptide XPD1-162
could not be tested. However, polypeptide XPD1-248 coprecipitated with p34 (Figure 6C), placing the p34-interaction
domain of XPD protein in the N-terminal 248 amino acids
(Figure 7). Thus, the N-terminal region of the XPD
polypeptide is involved in multiple interactions (Figure 7).
Mapping Interactions of p44 and p34 with Other Proteins.
The truncated polypeptides p441-240 and p441-166 coprecipitated with XPD, XPB, and p34 proteins (Figure 6D),
defining an interaction domain in the N-terminal 166 amino
acids of p44. The C-terminal region of p44 containing a
putative zinc-finger motif (Humbert et al., 1994) is apparently
not required for these interactions. However, our results with
full-length p44 and p34 proteins indicated a particularly
strong interaction. Hence, the region of p44 distal to amino
acid 240 may also be involved in its interaction with p34.
Regions involved in the interaction of p34 with other
TFIIH proteins were mapped using the truncations p341-245
and p341-134. The larger polypeptide co-precipitated with
both XPB and XPD proteins, but the smaller polypeptide
did not (Figure 6E), suggesting that the region of p34
between amino acids 134 and 245 is required for its
interaction with these proteins (Figure 7). Both p34 truncations co-precipitated with p44 protein (Figure 6E), indicating
the presence of a p44-interacting domain in the N-terminal
134 amino acids of p34 protein (Figure 7).
Mapping Domains for Interaction of XPG Protein with
p62, XPB, and XPD Proteins. To define domains in XPG
protein required for its interactions with p62, XPB and XPD
(see above) we generated the polypeptides XPG1-377 (containing an evolutionarily conserved N-terminal motif) (Scherly et al., 1993), XPG747-928 (containing a conserved C-terminal motif) (Scherly et al., 1993), and XPG611-753 (containing
a conserved motif rich in acidic amino acids) (Scherly et
al., 1993). XPG1-377 and XPG747-928 co-precipitated with
full-length XPB and XPD proteins (Figure 6F). Hence, both
the N-terminal 377 amino acids of XPG protein and the
C-terminal region comprising amino acids 747-928 are
required for the XPG-XPB and XPG-XPD interactions
(Figure 7). Polypeptides XPG1-377 and XPG611-753 did not
interact with p62 or p44 proteins, but XPG747-928 did (Figure
6F). Thus the conserved C-terminal region of XPG protein
is required for interactions with the XPB, XPD, p62, and
p44 subunits of TFIIH (Figure 7). Polypeptide XPG747-928
did not precipitate with the irrelevant proteins ERCC1,
Swi10, C-Fos, or C-Jun (data not shown).
Further confirmation of these XPG interactions was
obtained by examining pairwise interactions between fulllength XPG protein and various truncated TFIIH subunits.
Polypeptide p621-65 co-precipitated with XPG protein (Figure
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FIGURE 6: Qualitative summary of interaction domains in the XPB, XPD, p34, p62, and p44 subunits of TFIIH and in XPG protein, based
on pairwise interactions observed in Vitro. In each panel the full-length protein is represented above.

6A). As already indicated this region of p62 is also required
for its interaction with XPB and XPD proteins (Figure 7).
XPB1-387 but not the smaller polypeptide XPB1-198 interacted
with XPG protein (Figure 6B), defining a region of XPB
protein between amino acids 198 and 387 which is required
for its interaction with XPG protein (Figure 7). The
truncated polypeptide XPG747-928 but not XPG1-377 precipitated with XPB1-305 (Figure 6F), suggesting that a region of
XPB protein between amino acids 198 and 305 is required

for interaction with the C-terminal region of XPG protein.
Additionally, XPG1-377 interacted with polypeptide XPB1-387
(Figure 6F), suggesting that a region of XPB protein between
amino acids 305 and 387 is required for interaction with the
N-terminal region of XPG protein.
The truncated polypeptide XPD1-162 co-precipitated with
XPG747-928 containing the conserved C-terminal motif (Figure 6C) but not with XPG611-753 containing just the acidic
motif (data not shown). Hence, the N-terminal 162 amino
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FIGURE 7: Diagrammatic representation of regions of the p62, XPB, XPD, p44, p34, and XPG linear polypeptides which are required for
interactions with each other. These regions are necessary for the interactions shown, but it has not been determined that they are sufficient.

acids of XPD protein are required for interaction with a
C-terminal region of XPG protein. Since XPD protein also
interacted with an N-terminal domain in XPG protein (see
above), we examined the interaction between various truncated XPD polypeptides and the N-terminal fragment
XPG1-377. Polypeptide XPD1-434 co-precipitated with
XPG1-377, but the smaller polypeptides XPD1-324 and XPD1-162
did not (Figure 6C). The region between XPD amino acid
residues 324 and 434 is thus apparently required for its
interaction with the N-terminal region of XPG (Figure 7).
DISCUSSION
Systematic examination of the immunoprecipitation of
proteins derived by in Vitro translation of multiple cloned
genes indicate interactions between five of the subunits of
the human RNAP II transcription/NER complex TFIIH,
between four of these subunits and the NER protein XPG,
and between the XPG and CSB proteins. In addition,
polypeptide domains required for these interactions have been
approximately mapped. An extension of these studies,
including definitive demonstration of their biological relevance, will require further experiments that are beyond the
province of the present study, and these are planned for the
future. It is additionally important to bear in mind in living
cells the pairwise interactions defined in this study may be
substantially modified by the presence of additional proteins
which are members of the TFIIH complex and/or proteins
involved in NER.

The human XPB, XPD, p62, and p44 proteins were found
to interact with each other in each pairwise combination
tested. An interaction between XPB and XPD has been
previously implicated in the literature (Drapkin et al., 1994;
Shaeffer et al. 1994). In those experiments (Reardon et al.,
1993) mixing extracts of XP-B and XP-D cells resulted in
only marginal complementation of defective NER, although
each corrected defective repair in other XP cell extracts, thus
suggesting a stable complex between the two proteins.
However, these studies involved the use of crude extracts
and could not exclude the possibility that the XPB-XPD
interaction was mediated through another protein(s). The
present experiments suggest that XPB and XPD interact
directly, though we cannot definitively rule out the possibility
of a third “bridging” protein. Furthermore, the use of
truncated polypeptides indicates that just the N-terminal
regions of both proteins are required for their interaction.
An interaction between p62 and XPB protein also suggested
in earlier studies (van Vuuren et al., 1994) suffers from the
same interpretive limitation. Additionally, those studies
failed to detect an interaction between p62 and XPD proteins.
Our analysis indicates that p62 protein interacts directly with
both XPB and XPD and that the N-terminal 65 amino acid
region of p62 is sufficient for these interactions. The regions
of the XPB and XPD proteins required for their interactions
with p62 protein differ from those required for interaction
between them. The 34 and 44 kDa subunits of TFIIH
apparently interact strongly, possibly through distinct do-
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mains located near the N- and C-terminus of each protein.
Additionally, p44 protein interacts with XPB, XPD, and with
p62 (in the two hybrid system), and p34 interacts with XPB
and XPD proteins. We did not detect interactions between
p62 protein and p34 protein (Table 1). However, recent
indirect studies suggest that these proteins may indeed
interact in ViVo (Tong et al., 1995).
The structure of yeast TFIIH has also been investigated
(Aboussekhra et al., 1995; Bardwell, A. J., et al., 1993;
Bardwell, L., et al., 1994). A comparison with the results
of the present study indicates some differences. Unlike XPB
protein which interacts with the XPD, p62, and p34 proteins,
the homologous yeast Ssl2 protein was shown to interact
only with Rad3 (human XPD) protein, and this interaction
required the use of relatively high concentrations of purified
Rad3 protein (Bardwell, L., et al., 1994). This result is
consistent with the independent observation that yeast Ssl2
protein is apparently loosely bound to the core TFIIH
complex, since highly purified yeast TFIIH is depleted of
Ssl2 protein (Svejstrup et al., 1995; Wang et al., 1994). The
interaction between human p44 and XPD proteins is mirrored
in the yeast Ssl1/Rad3 interaction previously documented
(Bardwell, L., et al., 1994). However, in contrast to the
interaction between the human p62 and XPD proteins
observed in the present study, no interaction was observed
between the homologous Tfb1 and Rad3 proteins (Bardwell,
L., et al., 1994), and the interaction between the yeast TFB1
and Ssl1 proteins (Bardwell, L., et al., 1994) was not mirrored
by a detectable interaction between the corresponding human
p62 and p44 proteins. Hence, the precise architectural
organization of the human and yeast TFIIH complexes may
differ.
A notable similarity with respect to human and yeast
TFIIH is its apparent association with human XPG (yeast
Rad2) protein. In Vitro-translated Rad2 protein has been
shown to interact with purified TFIIH (Bardwell, A. J., et
al., 1994). More refined studies demonstrated that Rad2
interacts specifically with both Tfb1 and Ssl2 proteins
(Bardwell, A. J., et al., 1994). In the present study we have
observed that XPG protein interacts with the human homologs of Ssl2 (XPB) and Tfb1 (p62) proteins. Additionally,
we observed interactions between XPG and the XPD and
p44 subunits of TFIIH. Thus XPG protein apparently
associates with multiple subunits of human TFIIH. XPG is
a junction-specific endonuclease required for incisions 3′ to
sites of base damage during NER in human cells (O’Donovan
et al., 1994). Additionally, as indicated in the introduction,
the XPG gene as well as the XPB and XPD genes are
implicated in the combined clinical syndrome of XP/CS, and
mutations in the XPB and XPD genes can also result in the
NER-defective form of the disease TTD.
The complex clinical phenotypes of CS and TTD cannot
be obviously reconciled with defects in the NER function
of the XPB and XPD proteins. This has led to the hypothesis
that these diseases may reflect defects in the transcription
function of these proteins (Vermeulen et al., 1994). Such
defects are presumably subtle, otherwise they would not be
expected to be compatible with embryogenesis. The hypothesis that the molecular pathology of XP-B/CS and XPD/CS derives from defects in proteins with known functions
in transcription suggests a similar role for the XPG protein.
This protein has no experimentally proven function in
transcription. However, its intimate association with multiple
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subunits of TFIIH suggests that certain mutations in XPG
protein may affect the function of TFIIH. In this regard it
may be informative to map mutations in the XPG gene in
individuals from the XP-G complementation group who are
and are not simultaneously afflicted with CS. It has also
been suggested that XPG protein may be a critical link in
the postulated exchange of TFIIH between a complex
required for transcription (holoTFIIH) and one required for
NER (the nucleotide excision repairosome) (Svejstrup et al.,
1995). Mutations in XPG protein may interfere with such
exchange and thereby compromise the availability of TFIIH
for RNA polymerase II transcription.
The clinical features of CS in individuals who also
manifest XP are indistinguishable from those observed in
individuals who harbor the syndrome without XP (Nance &
Berry, 1992). This suggests that the products of the CSA
and CSB genes may also be involved in RNAP II transcription. CSA protein has indeed been shown to interact with
the p44 component of TFIIH and with CSB protein (Henning
et al., 1995). The demonstration in the present studies that,
in addition to its interaction with multiple components of
TFIIH, XPG protein also interacts with CSB protein lends
support to a possible role(s) of XPG protein in transcription.
ACKNOWLEDGMENT
We are grateful to Drs. Jane and Lee Bardwell for their
help during the early phases of this study. We also thank
our laboratory colleagues for stimulating discussions and for
critical evaluation of the manuscript.
REFERENCES
Aboussekhra, A., Biggerstaff, M., Shivji, M. K. K., Vilpo, J. A.,
Moncollin, V., Podust, V. N., Protic, M., Hübscher, U., Egly,
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